Skip to main content

Table 4 Tumor response to HD IL-2

From: A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

 

Prior Ipi only n = 52

No prior ICB n = 276

Total n = 328

 

n

%

n

%

n

%

CR

1

1.92

9

3.26

10

3.05

PR

10

19.23

25

9.06

35

10.67

SD

15

28.85

74

26.81

89

27.13

PD

23

44.23

158

57.25

181

55.18

Missing

3

5.77

10

3.62

13

3.96

Total

52

100

276

100

328

100

 

n

%

n

%

n

%

CR + PR

11

21.15

34

12.32

45

13.72

CR + PR + SD

26

50

108

39.13

134

40.85